Catalysts for Genentech Inc
166 tracked
May 17, 2018
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
May 11, 2018
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
May 11, 2018
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Apr 30, 2018
approval
TECENTRIQ (ATEZOLIZUMAB) — FDA approval
atezolizumab
→
Mar 22, 2018
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Mar 22, 2018
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Mar 13, 2018
approval
TECENTRIQ (ATEZOLIZUMAB) — FDA approval
atezolizumab
→
Nov 16, 2017
approval
GAZYVA (OBINUTUZUMAB) — FDA approval
obinutuzumab
→
Nov 16, 2017
approval
GAZYVA (OBINUTUZUMAB) — FDA approval
obinutuzumab
→
Aug 30, 2017
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
May 22, 2017
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
May 22, 2017
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Apr 17, 2017
approval
TECENTRIQ (ATEZOLIZUMAB) — FDA approval
atezolizumab
→
Mar 30, 2017
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Mar 30, 2017
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Sep 23, 2016
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Sep 23, 2016
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Jul 25, 2016
approval
KADCYLA (ADO-TRASTUZUMAB EMTANSINE) — FDA approval
trastuzumab emtansine
→
May 18, 2016
approval
TECENTRIQ (ATEZOLIZUMAB) — FDA approval
atezolizumab
→
Apr 28, 2016
approval
KADCYLA (ADO-TRASTUZUMAB EMTANSINE) — FDA approval
trastuzumab emtansine
→
Feb 26, 2016
approval
GAZYVA (OBINUTUZUMAB) — FDA approval
obinutuzumab
→
Sep 23, 2015
approval
GAZYVA (OBINUTUZUMAB) — FDA approval
obinutuzumab
→
Aug 18, 2015
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Aug 18, 2015
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
May 29, 2015
approval
KADCYLA (ADO-TRASTUZUMAB EMTANSINE) — FDA approval
trastuzumab emtansine
→
Dec 24, 2014
approval
GAZYVA (OBINUTUZUMAB) — FDA approval
obinutuzumab
→
Nov 13, 2014
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Jul 11, 2014
approval
KADCYLA (ADO-TRASTUZUMAB EMTANSINE) — FDA approval
trastuzumab emtansine
→
Jun 27, 2014
approval
GAZYVA (OBINUTUZUMAB) — FDA approval
obinutuzumab
→
Nov 1, 2013
approval
GAZYVA (OBINUTUZUMAB) — FDA approval
obinutuzumab
→